Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash pruritic23.03.13.030---
Renal colic20.02.03.0100.003717%
Renal cyst16.27.01.001; 20.01.04.0010.001239%-
Renal disorder20.01.02.0020.060841%-
Renal failure20.01.03.0050.052291%-
Renal pain20.02.03.0030.005824%-
Renal papillary necrosis05.07.02.001; 14.07.02.001; 20.01.07.0020.001239%-
Renal tubular acidosis14.01.01.005; 20.05.03.0030.016109%-
Renal tubular disorder20.05.03.0040.004956%-
Renal tubular necrosis20.01.07.0030.003098%-
Respiratory arrest22.02.01.009---
Respiratory disorder22.02.07.002---
Retching07.01.07.0020.003717%-
Retinal detachment06.09.03.003; 12.01.04.0040.001239%
Retinal vein thrombosis06.10.01.003; 24.01.07.0020.001239%-
Retinopathy06.10.02.001; 24.03.07.0030.003098%
Rhinitis11.01.13.004; 22.07.03.006--
Rhinitis allergic10.01.04.003; 22.04.04.0030.003346%
Seborrhoeic keratosis16.26.01.008; 23.10.01.0080.001239%-
Second primary malignancy16.16.01.0140.003717%
Sickle cell anaemia with crisis01.04.02.0010.245221%-
Skin discolouration23.03.03.0050.017719%-
Skin disorder23.03.03.007---
Skin reaction10.01.03.019; 23.03.03.0130.003346%-
Skin ulcer23.07.03.003; 24.04.03.0070.011028%
Sleep disorder19.02.04.001---
Sluggishness08.01.01.0040.001859%-
Sneezing22.12.03.0240.002478%
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.027---
Splenic infarction01.09.02.004; 24.04.08.024---
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 18 Pages